European Quality In Preclinical Data


Members of the EQIPD consortium have been pivotal in producing substantial evidence which suggests that the robustness, rigor and validity of preclinical research is limited and that this provides a barrier to the effective and efficient development of new drugs. We believe there is a need for simple, sustainable solutions that facilitate data quality without impacting innovation and freedom of research.

The European Quality In Preclinical Data (EQIPD) project proposes to pool resources from both academia and industry to pilot this action in Neuroscience and Safety, facilitated by analysis of historical datasets held by EFPIA consortium members data management system developed for the Systematic Review & Meta-analysis Facility (SyRF).

Learn more

EQIPD Objectives


Define those variables in study design and data analysis that influence outcome in preclinical Neuroscience (psychosis and Alzheimer’s disease) and Safety studies conducted in industry; and establish whether these are the same variables which influence outcome in academia.


Define the components which will make up the EQIPD quality management system.


Define consensus quality management recommendations for non-regulated R&D.


Validate the feasibility of the quality management system in prospective studies.


Deliver an online educational platform providing certificated education and training in the principles and application of quality and rigour.


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777364. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.